Pharmaceutical

ChromaDex wins orphan designation for rare ataxia drug

The company will be filing an IND for nicotinamide riboside chloride (NRC), which has received both orphan and rare pediatric designations.

Jun 8, 2024 - 04:00
ChromaDex wins orphan designation for rare ataxia drug
The company will be filing an IND for nicotinamide riboside chloride (NRC), which has received both orphan and rare pediatric designations.
Read the original article

Tags:

Previous Article

ASCO24: Another win for Opdivo/Yervoy in first-line HCC despite uncertainties

Next Article

FDA admonishes Jiangsu Hengrui’s manufacturing site following inspection

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Historic approval of sickle cell gene therapies met with cautious optimism by experts at ASH

STAT+: Historic approval of sickle cell gene therapies ...

Dec 9, 2023

TREAT California embarks on plan to earn $5bn for psychedelic research

TREAT California embarks on plan to earn $5bn for psych...

Oct 7, 2023

STAT+: Epic and Microsoft’s AI collaboration, Amazon and 3M, & Abbott’s CGM momentum

STAT+: Epic and Microsoft’s AI collaboration, Amazon an...

Apr 23, 2023